⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29429113 | 0.75 | — | — | |
| SCHEMBL29987283 | 0.75 | — | — | |
| SCHEMBL31444949 | 0.75 | — | — | |
| SCHEMBL1427764 | 0.75 | — | — | |
| SCHEMBL845314 | 0.75 | — | — | |
| SCHEMBL502743 | 0.75 | — | — | |
| SCHEMBL31345073 | 0.75 | — | — | |
| SCHEMBL898931 | 0.75 | — | — | |
| SCHEMBL1922166 | 0.75 | — | — | |
| SCHEMBL29503943 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739307-A2 | TARGETED EPIGENETIC THERAPIES FOR DISORDERS OF PROGRANULIN DEFICIENCY | The General Hospital Corporation (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-4626546-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2025-10-08 | — | — | EP | disclosed |
| US-20250282782-A1 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | GENZYME CORP (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250230157-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | RAPPORT THERAPEUTICS, INC. | 2025-07-17 | — | — | US | disclosed |
| US-20250221988-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI), INC. (CN) | 2025-07-10 | — | — | US | disclosed |
| US-12304908-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | RAPPORT THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-20250066357-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2025-02-27 | — | — | US | disclosed |
| EP-4504716-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | Cullgen (Shanghai), Inc. (CN) | 2025-02-12 | — | — | EP | disclosed |
| WO-2025010291-A2 | TARGETED EPIGENETIC THERAPIES FOR DISORDERS OF PROGRANULIN DEFICIENCY | THE GENERAL HOSPITAL CORPORATION (US) | 2025-01-09 | — | — | WO | disclosed |
| US-12187721-B2 | Protein tyrosine phosphatase inhibitors | ARRAY BIOPHARMA INC. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-2571883-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| WO-2012170976-A2 | COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY | MERCK PATENT GMBH (DE) | 2012-12-13 | — | — | WO | disclosed |
| US-8293769-B2 | CSF-1R inhibitors, compositions, and methods of use | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| EP-2451812-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20120108568-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-05-03 | — | — | US | disclosed |
| WO-2011146336-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-11-24 | — | — | WO | disclosed |
| WO-2011006074-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| US-20100130490-A1 | CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE | NOVARTIS AG (CH) | 2010-05-27 | — | — | US | disclosed |
| EP-2152700-A1 | CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE | Novartis Ag (CH) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008144062-A1 | CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE | NOVARTIS AG (CH) | 2008-11-27 | — | — | WO | disclosed |